Abstract:Non-small cell lung cancer (NSCLC) is still the leading cause of cancer-related deaths worldwide [ [1] Siegel R.L. Miller K.D. Jemal A. Cancer statistics. CA. Cancer J. Clin. 2018; 2018: 7-30 Crossref Scopus (6455) Google Scholar ]. Epidermal growth factor receptor (EGFR) gene mutations as driver oncogenes were first identified in NSCLC in 2004 and common mutations are associated with benefits from tyrosine kinase inhibitors (TKIs) [ 2 Lynch T.J. Bell D.W. Sordella R. et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2004; 350: 2129-2139 Crossref PubMed Scopus (10005) Google Scholar , 3 Mok T.S. Wu Y.L. Thongprasert S. et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 2009; 361: 947-957 Crossref PubMed Scopus (7038) Google Scholar , 4 Maemondo M. Inoue A. Kobayashi K. et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N. Engl. J. Med. 2010; 362: 2380-2388 Crossref PubMed Scopus (4631) Google Scholar , 5 Rosell R. Carcereny E. Gervais R. et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomized phase 3 trial. Lancet Oncol. 2012; 13: 239-246 Abstract Full Text Full Text PDF PubMed Scopus (4445) Google Scholar , 6 Shi Y. Zhang L. Liu X. et al. Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial. Lancet Oncol. 2013; 14: 953-961 Abstract Full Text Full Text PDF PubMed Scopus (372) Google Scholar ]. Therefore, EGFR mutation detection is a standard method in the management of NSCLC and it is crucial in the management of cases with common or unexpected genotyping results. Approximately 50% of Asian NSCLC patients have EGFR mutations [ [7] Shi Y. Au J.S. Thongprasert S. Srinivasan S. et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J. Thorac. Oncol. 2014; 9: 154-162 Abstract Full Text Full Text PDF PubMed Scopus (928) Google Scholar ]. The most common EGFR mutations are in-frame deletions of exon 19 (45% of all EGFR mutations) and point mutations in exon 21 p.L858R (35% of all EGFR mutations) [ 3 Mok T.S. Wu Y.L. Thongprasert S. et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 2009; 361: 947-957 Crossref PubMed Scopus (7038) Google Scholar , 4 Maemondo M. Inoue A. Kobayashi K. et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N. Engl. J. Med. 2010; 362: 2380-2388 Crossref PubMed Scopus (4631) Google Scholar ]. Clinical trials have indicated that mutations involving exons 18–21, especially for sensitive EGFR mutations, benefit from EGFR-TKI therapy [ 3 Mok T.S. Wu Y.L. Thongprasert S. et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 2009; 361: 947-957 Crossref PubMed Scopus (7038) Google Scholar , 5 Rosell R. Carcereny E. Gervais R. et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomized phase 3 trial. Lancet Oncol. 2012; 13: 239-246 Abstract Full Text Full Text PDF PubMed Scopus (4445) Google Scholar , 6 Shi Y. Zhang L. Liu X. et al. Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial. Lancet Oncol. 2013; 14: 953-961 Abstract Full Text Full Text PDF PubMed Scopus (372) Google Scholar ]. A study that explored the efficacy of EGFR-TKIs in patients with uncommon point mutations in exon 21 (at L861) and exon 18 (at G719) showed that the response rate was 57% [ [8] Wu J.Y. Yu C.J. Chang Y.C. et al. Effectiveness of tyrosine kinase inhibitors on uncommon epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer. Clin. Cancer Res. 2011; 17: 3812-3821 Crossref PubMed Scopus (381) Google Scholar ]. Exon 19 insertion has been reported as a sensitive mutation in some studies [ 9 He M. Capelletti M. Nafa K. et al. EGFR exon 19 insertions: a new family of sensitizing EGFR mutations in lung adenocarcinoma. Clin. Cancer Res. 2012; 18: 1790-1797 Crossref PubMed Scopus (130) Google Scholar , 10 Park J. Kondo C. Shimizu J. et al. EGFR exon 19 insertions show good response to gefitinib, but short time to progression in Japanese patients. J. Thorac. Oncol. 2014; 9: e10-e11 Abstract Full Text Full Text PDF PubMed Scopus (6) Google Scholar , 11 Iyevleva A.G. Mitiushkina N.V. Karaseva N.A. et al. Lung carcinomas with EGFR exon 19 insertions are sensitive to gefitinib treatment. J. Thorac. Oncol. 2014; 9: e31-3 Abstract Full Text Full Text PDF PubMed Scopus (15) Google Scholar , 12 Lin Y.T. Liu Y.N. Wu S.G. et al. Epidermal growth factor receptor tyrosine kinase inhibitor-sensitive exon 19 insertion and exon 20 insertion in patients with advanced non-small-cell lung cancer. Clin. Lung Cancer. 2016; 18: 324-332 Abstract Full Text Full Text PDF PubMed Scopus (29) Google Scholar ]. Its prevalence is rare and it accounts for only 0.5–1% of all EGFR mutations [ 9 He M. Capelletti M. Nafa K. et al. EGFR exon 19 insertions: a new family of sensitizing EGFR mutations in lung adenocarcinoma. Clin. Cancer Res. 2012; 18: 1790-1797 Crossref PubMed Scopus (130) Google Scholar , 12 Lin Y.T. Liu Y.N. Wu S.G. et al. Epidermal growth factor receptor tyrosine kinase inhibitor-sensitive exon 19 insertion and exon 20 insertion in patients with advanced non-small-cell lung cancer. Clin. Lung Cancer. 2016; 18: 324-332 Abstract Full Text Full Text PDF PubMed Scopus (29) Google Scholar ]. Therefore, the clinical efficacy of EGFR-TKIs in patients with exon 19 insertion had never been reported in a large cohort. Also, the clinical responsiveness to EGFR-TKIs in Chinese patients is not clear. Due to the limitations of first-generation testing techniques, not all types of uncommon EGFR mutations are detected. Some EGFR-mutation-negative patients might be false negative and these patients could have poor prognosis because of not receiving EGFR-TKI treatment. With the development of accurate detection technologies, more uncommon EGFR mutations have been detected. Next-generation sequencing (NGS) technology is potentially eligible for emerging molecular therapeutics in NSCLC. Here, we report a case to indicate that advanced NSCLC harboring the EGFR exon 19 insertion (p.I740_K745insIPVAIK) is sensitive to icotinib.

A Patient of Advanced NSCLC with a New EGFR Exon 19 Insertion Mutation and Its Response to EGFR-TKIs

Different Stories for Different EGFR Exon 19 Deletion Variants

Lung adenocarcinoma patient with EGFR 19 exon insert mutation and its response to icotinib

P1.01-111 EGFR Exon20 Insertion Patients Treated with First-Line Chemotherapy in Non-Small Cell Lung Cancer

EGFR-tyrosine Kinase Inhibitor Treatment in a Patient with Advanced Non-Small Cell Lung Cancer and Concurrent Exon 19 and 21 EGFR Mutations: A Case Report and Review of the Literature.

Uncommon EGFR Mutations in a Cohort of Chinese NSCLC Patients and Outcomes of First-Line EGFR-TKIs and Platinum-Based Chemotherapy.

Efficacy of Targeted Therapy in Patients with Non-Small Cell Lung Cancer Harboring Very Rare Mutations in EGFR Exon 18

P3.02-027 Lung Adenocarcinoma Patient with EGFR 19 Exon Insert Mutation: I740_K745insIPVAIK and Its Response to Icotinib: A Case Report

Response to Afatinib in a Patient with NSCLC Harboring Novel EGFR Exon 20 Insertion Mutations

P76.98 NSCLC Patients with Rare EGFR Mutations in Exons 18 and 19 Benefits from Treatment with EGFR Tyrosine Kinase Inhibitors

The novel EGFR mutations (p.E746_S752delinsI, p.T751_I759delinsG, p.L747_S752delinsAA) in patients with non-small cell lung cancer and the clinical treatment strategy: three case reports

Treatment of Uncommon EGFR Mutations in Non-Small Cell Lung Cancer: New Evidence and Treatment

EGFR Exon 18 Mutations in Advanced Non-Small Cell Lung Cancer: A Real-World Study on Diverse Treatment Patterns and Clinical Outcomes

Patients Harboring Uncommon EGFR Exon 19delins Variants of Advanced Non-Small-cell Lung Cancer and Response to Osimertinib: A Multi-Center Retrospective Study

A Lung Cancer Patient Harboring a Rare Oncogenic EGFR Exon 20 V786M Mutation Responded to a Third-Generation Tyrosine Kinase Inhibitor: Case Report and Review of the Literature

Comparison of clinical outcome and efficacy of patients with advanced non-small cell lung cancer Harbouring different epidermal growth factor receptor mutations

Characteristics, treatment patterns, and clinical outcomes in patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertions

A Multicenter-Retrospective Study of Non-Small-cell Lung Carcinoma Harboring Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations: Different Subtypes of EGFR Exon 19 Deletion-Insertions Exhibit the Clinical Characteristics and Prognosis of Non-Small Cell Lung Carcinoma

Real-world Response and Outcomes in Patients with NSCLC with EGFR Exon 20 Insertion Mutations

[Advances in Treatment of Non-small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations].

EGFR Exon20 Insertion Mutations in Non-Small Cell Lung Cancer: Clinical Implications and Recent Advances in Targeted Therapies.